1. Home
  2. BCYC

as 04-18-2025 1:31pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Founded: 2009 Country:
United Kingdom
United Kingdom
Employees: N/A City: CAMBRIDGE
Market Cap: 511.4M IPO Year: 2019
Target Price: $29.14 AVG Volume (30 days): 438.9K
Analyst Decision: Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.90 EPS Growth: N/A
52 Week Low/High: $6.10 - $28.67 Next Earning Date: 05-01-2025
Revenue: $35,275,000 Revenue Growth: 30.76%
Revenue Growth (this year): -8.47% Revenue Growth (next year): 0.27%

BCYC Daily Stock ML Predictions

Stock Insider Trading Activity of Bicycle Therapeutics plc (BCYC)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Skynner Michael BCYC CHIEF TECHNOLOGY OFFICER Apr 2 '25 Sell $7.75 1,852 $14,292.52 122,908
Thompson Travis Alvin BCYC CHIEF ACCOUNTING OFFICER Apr 2 '25 Sell $7.75 319 $2,499.52 31,936
Young Alethia BCYC Chief Financial Officer Apr 2 '25 Sell $8.02 215 $1,724.30 45,390
Milnes Alistair BCYC CHIEF OPERATING OFFICER Apr 2 '25 Sell $7.75 2,171 $16,850.90 97,617
Lee Kevin BCYC CHIEF EXECUTIVE OFFICER Apr 2 '25 Sell $7.75 5,669 $43,612.10 489,697

Share on Social Networks: